Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P22674
UPID:
CCNO_HUMAN
Alternative names:
-
Alternative UPACC:
P22674; A8K1W5; Q0P6J2; Q9H6B0; Q9UMD5
Background:
Cyclin-O plays a pivotal role in the generation of multiciliated cells, essential for respiratory health. It operates downstream of MCIDAS, facilitating mother centriole amplification and maturation, crucial for cilia formation.
Therapeutic significance:
Cyclin-O's dysfunction is linked to Primary Ciliary Dyskinesia 29, characterized by recurrent respiratory infections and bronchiectasis due to defective cilia. Understanding Cyclin-O's role could unveil new therapeutic avenues.